Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ 	Cisplatin and Cyclophosphamide	Toxicity	-1	-1	Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of IFN-�?3.
Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ 	Cisplatin and Cyclophosphamide	Toxicity	1105	1240	Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of IFN-γ.
Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ 	Cisplatin and Cyclophosphamide	Overall survival at 3 years	926	1013	Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached).
Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ 	Cisplatin and Cyclophosphamide	Full clinical responses	1014	1104	Complete clinical responses were observed in 68% with IFN-γ versus 56% in controls (n.s.).
Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ 	Cisplatin and Cyclophosphamide	Progression-free survival after 3 years	681	925	Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (P = 0.031, relative risk of progression 0.48, confidence interval 0.28–0.82).
Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ 	Cisplatin and Cyclophosphamide	Progression-free survival after 3 years	-1	-1	Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (P = 0.031, relative risk of progression 0.48, confidence interval 0.28�??0.82).
Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ 	Cisplatin and Cyclophosphamide	Full clinical responses	-1	-1	Complete clinical responses were observed in 68% with IFN-�?3 versus 56% in controls (n.s.)
